Published in TB and Outbreaks Week, February 28th, 2006
"The present study was planned to evaluate the chemotherapeutic potential of oral solid lipid nanoparticles (SLNs) incorporating rifampicin, isoniazid, and pyrazinamide against experimental tuberculosis.
"The SLNs were prepared by the 'emulsion solvent diffusion' technique with an encapsulation efficiency of 51±5% for rifampicin, 45±4% for isoniazid and 41±4% for pyrazinamide," investigators in India report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.